AKT1 and posterior cortical atrophy: In the last decade, new therapies have been approved for early localized [40] and advanced PCA [41], as well as evolving therapies such as cancer vaccines, chimeric antigen receptor T (CAR-T) cells, bispecific T cell engagers (BiTEs), other targeted agents (e.g., AKT inhibitors) and various combination therapies [41] have marked an era of precision medicine for PCA.